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Introduction: Rapamycin acts synergistically with platinum agents to induce apoptosis and inhibit proliferation
in breast cancer cell lines. Combination of everolimus also known as RAD001 (oral mammalian target of rapamycin
(mTOR) inhibitor) and carboplatin may have activity in metastatic triple-negative breast cancer (TNBC).
Methods: The primary objective of this study was to determine clinical benefit rate (CBR), that is (complete
remission (CR) + partial remission (PR) + stable disease (SD) lasting ≥6 months) and the toxicity of everolimus/
carboplatin in women with metastatic TNBC. Prior carboplatin was allowed. Treatment consisted of intravenous
carboplatin area under the curve (AUC) 6 (later decreased to AUC 5 and subsequently to AUC 4) every 3 weeks
with daily 5 mg everolimus.
Results: We enrolled 25 patients in this study. Median age was 58 years. There were one CR, six PRs, seven SDs and
eight PDs (progression of disease). CBR was 36% (95% confidence interval (CI) 21.1 to 57.4%). One SD was achieved
in a patient progressing on single agent carboplatin. The median progression free survival (PFS) was 3 months
(95% CI 1.6 to 4.6 months) and overall survival (OS) was 16.6 months (95% CI 7.3 months to not reached). There
were seven patients (28%) with ≥ grade 3 thrombocytopenia; three (12%) with grade 3 neutropenia (no bleeding/
febrile neutropenia) and one (4%) with grade 3 anemia. Greater hematological toxicity was seen in the first seven
patients treated with carboplatin AUC5/6. After the amendment for starting dose of carboplatin to AUC 4, the
regimen was well tolerated with only one out of 18 patients with grade 3 neutropenia and two patients with
grade 3 thrombocytopenia. There was only one case of mucositis.
Conclusion: Everolimus-carboplatin was efficacious in metastatic TNBC. Dose limiting hematological toxicity was
observed when AUC5/6 of carboplatin was combined with everolimus. However, carboplatin AUC 4 was well
tolerated in combination with everolimus with continuing responses.
Trial registrations: ClinicalTrials.gov NCT01127763.Introduction
Triple negative breast cancer (TNBC) is a breast cancer
subtype characterized by the lack of expression of estrogen
receptor (ER), progesterone receptor (PR) as well as HER-2
neu amplification (grade 3+ on immunohistochemistry
(IHC) or fluorescent in-situ hybridization (FISH)-positive)* Correspondence: amy.tiersten@mssm.edu
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reproduction in any medium, provided the oron the cancer cells and constitutes about 15% of all breast
cancers [1]. Women with TNBC tend to be younger and
demonstrate early recurrence (within the first 2 years),
higher histological grade, higher rate of visceral me-
tastasis and increased mortality rates when compared
to hormone-positive breast cancer [2]. Prognosis for
metastatic TNBC is especially poor with median survival
of only one year when compared to about 2 · 3 years with
other subtypes of breast cancer [3].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treatment of choice for triple-negative breast cancer and
chemotherapy remains the accepted standard. Many
chemotherapeutic agents have been reported to have
clinical activity either as single agents or in combination.
Seventy percent of breast cancers with breast cancer
(BRCA)-1 germline mutations are triple negative, which
suggests a shared carcinogenic pathway between the two
[4,5]. Both TNBC and BRCA-1-associated breast cancers
are particularly sensitive to DNA crosslinking agents
such as platinum compounds, due to defective DNA re-
pair by homologous recombination [6,7]. Lehmann et al.
used gene expression profiles to identify six TNBC sub-
types with distinct gene expressions and ontologies; each
responsive to unique therapeutic agents in vitro and in
xenograft models. BRCA-1 mutant and non-BRCA
mutant basal-like subtypes (BL-1 and BL-2) expressed
high levels of genes involved in cell proliferation and
DNA damage response. The representative cell lines of
these subtypes were highly sensitive to cisplatin [8]. In a
phase 2 study of cisplatin in BRCA-1-mutated metastatic
triple-negative breast cancer, overall response rates as
high as 80% (complete response (CR) rates of 45% and
PRes 35%) have been observed. Median time to progres-
sion was 12 months: 55% of patients had undergone
prior chemotherapy for metastatic disease [9]. Platinum
agent combinations with other chemotherapeutic agents
were evaluated in the metastatic setting in a retrospect-
ive study. Of the patients, 63.5% were triple negative.
The most common combination was Cisplatin and
ifosfamide, used in 70% of the subjects. Other chemo-
therapy combinations used were carboplatin-ifosfamide
(5.6%); cisplatin-ifosfamide-bevacizumab (4.2%); cisplatin-
gemcitabine (2.8%); cisplatin-docetaxel (4.2%); cisplatin-
cyclophosphamide (2.1%) and navelbine platine ifosfamide
(7.7%). Response rates to individual regimens were not
reported but the response rate to the platinum-based regi-
mens in TNBC was 33.3% versus 22.0% in the non-TNBC
group [10]. In another phase II study, the combination
of carboplatin with gemcitabine for metastatic TNBC
showed an overall response rate (ORR) of 32% [11].
Everolimus is a selective inhibitor of mammalian target
of Rapamycin (mTOR). The phosphotidyl-inositol 3 kin-
ase (PI3K)/AKT/mTOR pathway is known to be dysreg-
ulated in a wide spectrum of human cancers including
breast cancer [12]. mTOR acts via the PI3K-AKT signal-
ing pathway, leading to phosphorylation of targets inclu-
ding p70-S6 Kinase 1 (S6K1) and eukaryotic initiation
factor 4E binding protein 1 (4E-BP1). Through this path-
way, mTOR plays a key role in the regulation of many
cellular processes, including cell proliferation, survival,
and apoptosis [13].
Loss of phosphatase and tensin homolog (PTEN)
expression has been reported in 37 to 74% of metastatictriple-negative breast cancers [14-16], which results in
activation of the PI3K/PTEN/AKT/mTOR pathway,
making mTOR inhibitors also a potential molecular tar-
get for treating TNBC [17,18]. Activation of the PI3K/
AKT/mTOR pathway in breast cancer portends a worse
prognosis, increased aggressiveness and resistance to
treatment [19].
Everolimus has a potential to act directly on the tumor
cells by inhibiting tumor cell growth and proliferation as
well as indirectly by inhibiting angiogenesis, leading to
reduced tumor vascularity (via potent inhibition of tumor
cell hypoxia induced factor-1 (HIF-1) activity, vascular
endothelial growth factor (VEGF) production and VEGF-
induced proliferation of endothelial cells) [20,21].
There is also preclinical evidence suggesting that
everolimus enhances the sensitivity of breast cancer cell
lines to carboplatin resulting in synergistic inhibition of
cell proliferation and caspase-independent apoptosis
[22]. Mesenchymal-like TNBC subtype was found to be
extremely sensitive to dual PI3K/mTOR inhibition in
preclinical models [8]. In other preclinical studies, eve-
rolimus was found to have efficacy against basal-like
subtypes of TNBC especially if they expressed endothelial-
derived growth factor (EGFR) receptor or cytokeratin
(CK) 5/6 [23].
Everolimus has been evaluated in hormone-positive
and Her-2 positive MBC with promising results. In the
phase 3 BOLERO-2 trial, 724 patients with hormone-
positive metastatic breast cancer (MBC) were treated
with exemestane alone versus exemestane plus everoli-
mus. Progression-free survival (PFS) was 10.6 months in
the combination group versus 4.1 months in the exe-
mestane alone group (hazard ratio (HR) 0.36; 95% CI
0.27, 0.47; P <0.001). Response rates were 0.4% and 9.5%
respectively [24]. In preclinical models, mTOR inhibitors
synergize with trastuzumab and have shown to cause
complete regression of mouse Her-2-positive mammary
tumors [25]. In a phase I/II trial of trastuzumab combined
with mTOR inhibitor everolimus for Her-2-positive MBC,
partial responses were seen in 15% of patients and stable
disease lasting for at least 6 months in 19% (clinical bene-
fit rate (CBR) 34%) [26]. BOLERO-3 is a phase III trial
comparing vinorelbine and trastuzumab alone or in com-
bination with everolimus in 569 patients with metastatic
Her-2-positive breast cancer resistant to trastuzumab. The
preliminary findings of this study were presented in the
American Society of Clinical Oncology annual meeting in
2013. The median time to progression was 5.8 months in
the control arm and 7 months in the everolimus arm (HR
for progression 0.78; 95% CI 0.65, 0.95; P <0.01). The
response rates were not significantly different between the
two groups (41% in the everolimus arm versus 37.2% in
the non-everolimus arm). The data on overall survival, the
secondary endpoint of this study, are not yet mature [27].
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been tested for non-triple-negative MBC (12 patients
were hormone receptor-positive and 5 were Her-2-
overexpressing) in a phase 1 dose-determination study.
In this study 15 patients with pretreated MBC were
treated with weekly carboplatin, with an area under the
curve (AUC) of 2, and different dose levels of everolimus
(level I: 2.5 mg, level II: 5 mg, level III: 7.5 mg and level
IV: 10 mg). Three patients were each treated with levels
I through III and six were treated with level IV. Three
patients had PRes and three had stable disease (SD) last-
ing >24 weeks, making the CBR 40%. Median PFS was
19 weeks and overall survival (OS) was 35.3 weeks [28].
This is the first study that looks at an mTOR inhibitor
in combination with a platinum agent in triple-negative
breast cancer.
Methods
This was a single-institution phase II trial. The primary
objective of the study was to determine the clinical
benefit (CR + PRes + SD lasting ≥6 months) and toxicity
of everolimus and carboplatin combination in women
with metastatic TNBC who have had 0 to 3 prior chemo-
therapy regimens for metastatic disease.
The institutional review board (IRB) of the New York
University provided ethical approval for this study. All
patients were required to sign IRB-approved informed
consent in order to be eligible for the study. All the
enrolled patients were treated in compliance with the
Declaration of Helsinki. Eligible patients were women
with metastatic histologically confirmed triple-negative
breast cancer (ER <10%, PR <10%, HER-2neu IHC 0 or 1,
or FISH-negative). Additional eligibility criteria included
age ≥18 years; World Health Organization (WHO) per-
formance status ≤2; adequate bone marrow function (abso-
lute neutrophil count ≥1 · 5 × 109/L, platelets ≥75 × 109/L,
hemoglobin >9 g/dL); adequate liver function (serum
bilirubin ≤1 · 5 × upper limit of normal (ULN), inter-
national normalized ratio (INR) ≤1 · 5 for patients not
on warfarin and INR ≤3.0 for patients on warfarin, ala-
nine transaminase (ALT) and aspartate transaminase
(AST) ≤2 · 5 × ULN (≤5 × ULN in patients with liver me-
tastases)); patients on stable dose of lower molecular
weight heparin for >2 weeks at time of treatment; ad-
equate renal function (serum creatinine ≤1 · 5 × ULN);
fasting serum cholesterol ≤300 mg/dL or ≤7 · 75 mmol/L
and fasting triglycerides ≤2 · 5 × ULN (in case one or both
of these thresholds were exceeded, the patient could only
be included after initiation of appropriate lipid-lowering
medication); baseline lung computed tomography (CT)
scan or positron emission tomography (PET)/CT; oxygen
saturation ≥90% in room air; and negative serum preg-
nancy test within 7 days prior to starting treatment. Pa-
tients could have had 0 to 3 prior regimens for metastaticdisease and prior bevacizumab-treated patients were
eligible. Exclusion criteria included: history of having
received other anticancer therapies or investigational
drugs within 2 weeks of the start of the study drug;
major surgery or significant traumatic injury within
4 weeks; patients receiving chronic systemic cortico-
steroids at ≥20 mg/day or other immunosuppressive
agents; history of immunization with attenuated live
vaccines within one week of study entry; uncontrolled
brain or leptomeningeal metastases; other malignancies
within the past 3 years except for adequately treated
carcinoma of the cervix or basal or squamous cell carcin-
omas of the skin; uncontrolled medical conditions such as
symptomatic congestive heart failure of New York Heart
Association Class III or IV, unstable angina pectoris,
symptomatic congestive heart failure, myocardial infarc-
tion within 6 months of start of the study drug; serious
uncontrolled cardiac arrhythmia or any other clinically
significant cardiac disease; severely impaired lung function
(spirometry and diffusing capacity for carbon monoxide
(DLCO) that is 50% of the normal predicted value and/or
oxygen saturation that is 89% or lower at rest in room air);
uncontrolled diabetes (fasting serum glucose ≥1.5 × ULN);
uncontrolled severe infections; liver disease such as
cirrhosis, chronic active hepatitis or chronic persistent
hepatitis; known history of HIV seropositivity, impairment
of gastrointestinal function or gastrointestinal disease that
may significantly alter the absorption of everolimus (ul-
cerative disease, uncontrolled nausea, vomiting, diarrhea,
malabsorption or small bowel resection); active, bleed-
ing diathesis; pregnancy or lactation; prior treatment
with an mTOR inhibitor or known hypersensitivity to
mTOR inhibitors; history of noncompliance to medical
regimens; unwillingness to comply or inability to com-
ply with the protocol, or an ongoing alcohol or drug
addiction.
Baseline assessment
Patients were required to have baseline pulmonary func-
tion tests if their oxygen saturation was lower than 90%
on room air. Either PET/CT or CT chest/abdomen/pel-
vis or bone scan were obtained at baseline and then after
every two cycles of treatment (that is, every 6 weeks). At
baseline, tumor lesions were categorized as measurable
or non-measurable by the response evaluation criteria in
solid tumors (RECIST) 1 · 0. a physical examination, vital
signs, and tumor markers (carcinoembryonic acid (CEA)
and cancer antigen (CA) 27/29) were checked at baseline
and then every 3 weeks. A baseline electrocardiogram
was also obtained. Laboratory tests included a complete
blood count, prothrombin time (PT) (INR), blood chemis-
try and liver function tests, serum lipid profile and stand-
ard urinalysis dipstick assessment. All were screened for
hepatitis B and hepatitis C infection.
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According to the original study plan, carboplatin AUC 6
was to be given intravenously every 3 weeks: 5 mg of
everolimus was to be given daily with a three-patient run-
in and then 10 mg daily if there were no dose-limiting tox-
icities. Due to high incidence of severe thrombocytopenia
seen with carboplatin AUC 6, the dose of carboplatin was
first amended to AUC 5 on 2 August 2010 and then to
AUC 4 with 5 mg of everolimus (with no escalation of
everolimus to 10 mg) on 4 April 2011.
According to the most recent study plan, carboplatin
was administered with AUC of 4 on day 1 of every cycle,
and repeated every 3 weeks. Everolimus was provided by
Novartis. The patients were instructed to take 5 mg of
everolimus orally once daily continuously from study
day 1 until progression of disease or unacceptable toxicity.
Patients were instructed to take everolimus in the morn-
ing, at the same time each day.
Statistical methods
This study was a single-stage phase II trial. With 25
subjects (Figure 1), this study had 80% power to test the
null hypothesis that the clinical benefit rate (CR + PRes +
SD ≥6 months) is ≤0 · 10 versus the alternative hypothesis
that clinical benefit rate is ≥ 0 · 30. If the number of
responses (including CR + PR + SD ≥6 months) was six or
more, the hypothesis that P ≤0 · 10 would be rejected with
a target alpha error rate of 0 · 050 and an actual error rate
of 0 · 033. If the number of responses was five or less, the
hypothesis that P ≥0 · 30 would be rejected with a target
error rate of 0 · 200 (power of 80%) and an actual error














Figure 1 Consort figure.derived from benchmarks from prior studies in similar
patient populations.
Descriptive statistics were used to summarize the
patient demographic characteristics and adverse events.
The benefit rate was estimated along with the exact 95%
CI. Kaplan-Meier curves were provided for PFS and OS
in this study; the corresponding median survival times




Additional file 1: Table S1 shows the distributions of the
demographic characteristics of the 25 patients: 44% of pa-
tients had received no prior line of treatment for metastatic
disease, 28% had received one prior line of treatment, 24%
had received two prior lines of treatment and 4% had re-
ceived three prior lines of treatment for metastatic disease.
Efficacy
In this study clinical benefit (CR + PRes + SD of >30%
lasting more >6 months) was achieved in 9/25 patients
(36%; 95% CI 21 · 1, 57 · 4%). There was one patient with
CR, six with PRes, seven with SD and eight with PD.
One patient with CR and four with PR were on a carbo-
platin dose of AUC 4 combined with 5 mg of everolimus.
Two patients had stable disease lasting longer than
6 months. Three patients did not complete the first cycle
of chemotherapy for the following reasons: withdrawal of
consent in one patient; and rapid progression of disease in
two other patients. SD was achieved in one patient pro-
gressing on single-agent carboplatin at study entry. Twoxcluded (n=1)
creen failure) 
id not complete cycle 1 of 
rboplatin -everolimus due to
ithdrawal of consent (n=1);  
pid progression of disease 
=2) 
Figure 3 Overall survival curve in patients with triple-negative
breast cancer treated with everolimus and carboplatin.
Kaplan-Meier curve showing overall survival in patients with
triple-negative breast cancer who were treated with everolimus and
carboplatin. Median overall survival (OS) was 16 · 6 months (95% CI
7.3 months - not reached).
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toxicity.
Response by carboplatin dose
Among the four patients treated with carboplatin AUC 6
and everolimus 5 mg daily, there was one with PRes and
one with SD lasting longer than 6 months. Among the
three patients treated with carboplatin AUC 5, there was
one with PR and one with SD lasting longer than 6 months.
Among the 18 patients treated with AUC 4, there were
one with CR and four with PRes (response rate (RR) and
CBR 28%).
Kaplan-Meier curves for PFS and OS are shown in
Figures 2 and 3 respectively. The median PFS time was
3 months (95% CI 1 · 6, 4 · 6 months) and overall survival
time was 16 · 6 months (95% CI 7.3 months - not
reached).
Toxicity
Hematological toxicity (thrombocytopenia, neutropenia
and anemia) was the most common high-grade toxicity
observed especially in patients who were treated with
higher doses of carboplatin (AUC 5 and 6). Hematological
toxicity data are provided in Additional file 2: Table S2.
Seven patients (28%) had grade 3 or higher thrombo-
cytopenia. Five of these seven patients were treated with
carboplatin doses AUC 5 or 6. Since protocol amendment,
only two of the eighteen patients (11%) treated with car-
boplatin doses of AUC 4 had grade 3 thrombocytopenia.
Three patients (12%) had grade 3 neutropenia with two of
these patients being treated prior to second amendmentFigure 2 Progression-free survival curve. Kaplan-Meier curve
showing progression-free survival in patients with metastatic
triple-negative breast cancer who were treated with everolimus
and carboplatin. The median PFS time was 3 months (95% CI
1 · 6, 4 · 6 months).for carboplatin dose. There was no febrile neutropenia,
and no cases of severe bleeding. There was one case of
grade 3 anemia. Growth factor support was required in
seven patients (28%) and transfusion support in six
patients (24%).
Non-hematological toxicity data related to the treat-
ment are shown in Additional file 3: Table S3. This study
is notable for minimal incidence of mucositis (one
patient, 4%), that can probably be attributed to the
lower dose of everolimus used. The other grade 3 non-
hematological toxicities included dehydration (n = 1, car-
boplatin AUC 4), nausea and vomiting (n = 1, carboplatin
AUC 4), and hypersensitivity to carboplatin (n = 1, carbo-
platin AUC 4). Grade 3 insomnia (n = 1), headache (n = 1),
grade 3 cellulitis (n = 1), grade 3 elevation of INR in the
setting of infection (n = 1); grade 3 foot infection (n = 1)
and shortness of breath (n = 2) were also observed but
these adverse events were thought to be unrelated to
treatment. There have been no reports of interstitial lung
disease secondary to everolimus in our study patients.
The four patients in the AUC-6 carboplatin cohort
received 70% of the planned total dose of carboplatin,
the three patients in the AUC-5 cohort received 68% of
the planned dose and the 18 patients in the AUC-4 co-
hort received 64% of the total planned dose. This result
seems paradoxical but can be attributed to the fact that
in one patient in the AUC-4 group, carboplatin was dis-
continued after four cycles but the patient continued to
be stable on single-agent everolimus for 14 more cycles.
If we exclude that patient, 84% of the planned dose of
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teen patients (60%) required treatment interruptions and
nine (36%) patients required dose reductions. In seven
patients, the dose of carboplatin was further decreased
to AUC 3; in one patient carboplatin was discontinued
and the patient had long-lasting partial response on
single-agent everolimus. In five patients, the dose of
everolimus was decreased to 5 mg on alternate days.
Five patients (20%) were hospitalized for the following
reasons: hypersensitivity reaction to carboplatin, cellu-
litis (unrelated to treatment regimen), foot infection
(unrelated to treatment regimen), shortness of breath
(unrelated to treatment regimen), headache and dehy-
dration respectively.
Discussion
We demonstrated the efficacy of the combination of
everolimus with carboplatin in triple-negative metastatic
breast cancer. Everolimus 5 mg daily given orally and
carboplatin AUC 4 administered intravenously every
3 weeks was both safe and efficacious in metastatic
TNBC with a CBR of 36% and median PFS of 3 months.
When carboplatin was administered at a dose of AUC 5
or greater, higher incidence of grade 3 or higher hemato-
logical toxicity was observed. However, at the recom-
mended dose of carboplatin at AUC 4 the combination
regimen has been very well-tolerated and anti-tumor
responses were observed.
Combination of carboplatin and cetuximab, an anti-
EGFR agent, was recently studied in a phase II clinical
trial by Carey et al. for metastatic TNBC. The study
comprised two arms, arm 1 receiving cetuximab alone
with carboplatin added on progression, and arm 2
receiving cetuximab plus carboplatin from the beginning.
Of patients in arm 1, 32% and 52% of patients in the
combination arm had received no prior chemotherapy for
metastatic disease. The response rate to single-agent
cetuximab was 6% whereas with the combination of
cetuximab and carboplatin it was 17%. The dose of carbo-
platin administered in the above-mentioned study was
AUC 2 weekly for 3 weeks over a 28-day cycle. Our
patient population was similar to the Carey study with
44% of patients having received no prior treatment for
metastatic disease. However, the combination of carbopla-
tin and everolimus was able to achieve a much higher
response rate (28% in our study) despite a lower dose
of carboplatin, demonstrating synergy of the combin-
ation [29].
TNBC has been found to be sensitive to platinum-
based treatment due to inherent genomic instability. In a
series of 151 patients with metastatic TNBC, response
rates with treatment using platinum combination therapy
(cisplatin combined with either paclitaxel or vinorelbine)
was higher than with other chemotherapy regimens (42%versus 23%). In another small series of eight patients with
metastatic TNBC randomized to docetaxel/capecitabine
combination versus docetaxel/cisplatin combination, the
ORR was higher in the platinum-containing group that
also translated into improved PFS and OS [30].
The mTOR inhibitor everolimus has been recently
Food and Drug Administration-approved in combination
with exemestane for the treatment of metastatic hormone
receptor-positive breast cancer based on a significant im-
provement in PFS in the randomized phase III BOLERO-
2 trial [24]. However, mTOR inhibitors have not been
evaluated in a phase II or III study of TNBC. With TNBC
there is high frequency of PTEN loss, which leads to
mTOR activation. Moreover, it has been reported that
mTOR activation confers resistance to platinum agents
such as cisplatin, a phenomenon that is reversible by
addition of an mTOR inhibitor such as everolimus [31].
In a phase I trial combining everolimus and carbopla-
tin for metastatic breast cancer, patients were treated
with weekly carboplatin (AUC 2) and everolimus at escalat-
ing doses of 2 · 5 mg/d, 5.0 mg/d, 7 · 5 mg/d or 10.0 mg/d,
with 40% of patients receiving 10 mg/d. The study showed
a CBR in 6/14 patients (43%). Of note, 4/6 patients treated
with everolimus 10 mg/day had dose reductions due to
grade-3 or -4 hematological toxicity or grade-4 fatigue.
There was also a higher rate of mucositis (60%) observed,
compared to only 4% in our study, likely due to the lower
dose of everolimus. Grade-3 hematological toxicities ob-
served in the phase I combination trial (thrombocytopenia,
neutropenia and anemia) were comparable.
Strengths of our study are the prospective design and
a clinical end point looking at the clinical benefit rate.
While this study does not evaluate the contribution of
everolimus on the observed efficacy, given the encour-
aging results, a randomized phase II trial of carboplatin
alone versus carboplatin combined with everolimus in
TNBC is in development. Furthermore, we observed an
efficacy signal of everolimus in a patient who was pro-
gressing on single-agent carboplatin prior to treatment
and achieved SD when everolimus was added. Similarly,
a patient who had initially achieved PR with the combin-
ation maintained this response on single-agent everoli-
mus for 8 · 3 months after carboplatin was discontinued
secondary to neutropenia.
This trial has met the primary end point of demon-
strating clinical benefit and describing the safety profile
of everolimus and carboplatin combination in triple-
negative metastatic breast cancer. Carboplatin at AUC 4
when combined with 5 mg daily everolimus is safe and
efficacious.
Conclusions
Everolimus-carboplatin combination was efficacious in
metastatic TNBC. Dose-limiting hematological toxicity
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were combined with everolimus. However, carboplatin
AUC 4 was well tolerated in combination with everolimus,
with continuing responses.
Additional files
Additional file 1: Table S1. Demographics table.
Additional file 2: Table S2. Hematological toxicity table. This table
shows hematological toxicity observed in patients with triple-negative
metastatic breast cancer treated with everolimus and carboplatin
combination. Hematological toxicity is further separated by severity that
is, grade 1 to 2, grade 3 or grade 4. No cases of febrile neutropenia
were observed.
Additional file 3: Table S3. Non-hematological toxicity, which was
related to the treatment regimen table. This table shows non-hematological
toxicity observed in patients with triple-negative metastatic breast cancer
treated with everolimus and carboplatin combination, which was directly
related to the drug regimen. No grade-4-related toxicities were observed.
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